Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 4/2014

01-07-2014 | Review

Immunopathogenesis of idiopathic nephrotic syndrome with relapse

Authors: Djillali Sahali, Kelhia Sendeyo, Melanie Mangier, Vincent Audard, Shao Yu Zhang, Philippe Lang, Mario Ollero, Andre Pawlak

Published in: Seminars in Immunopathology | Issue 4/2014

Login to get access

Abstract

Idiopathic change nephrotic syndrome (INS), the most frequent glomerular disease in children and young adults, is characterized by heavy proteinuria and a relapsing remitting course. Although the mechanisms underlying the pathophysiology of proteinuria remain unclear, clinical and experimental observations suggest that lymphocyte and podocyte disturbances are two sides of the disease. The current hypothesis suggests that immune cells release a putative factor, which alters podocyte function resulting in nephrotic proteinuria. Besides T-cell abnormalities, recent evidence of B-cell depletion efficacy in sustained remissions added a new challenge in understanding the immunological mechanisms of INS. In this review, we discuss recent insights related to podocyte disorders occurring in INS and their relevance in human diseases.
Literature
1.
2.
Nakayama M, Katafuchi R, Yanase T, Ikeda K, Tanaka H, Fujimi S (2002) Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. Am J Kidney Dis 39:503–512PubMedCrossRef
3.
Mathieson PW (2007) Minimal change nephropathy and focal segmental glomerulosclerosis. Semin Immunopathol 29:415–426PubMedCrossRef
4.
Kestila M, Lenkkeri U, Mannikko M et al (1998) Positionally cloned gene for a novel glomerular protein—nephrin—is mutated in congenital nephrotic syndrome. Mol Cell 1:575–582PubMedCrossRef
5.
Boute N, Gribouval O, Roselli S et al (2000) NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 24:349–354PubMedCrossRef
6.
Hinkes B, Wiggins RC, Gbadegesin R et al (2006) Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet 38:1397–1405PubMedCrossRef
7.
Kaplan JM, Kim SH, North KN et al (2000) Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 24:251–256PubMedCrossRef
8.
Reiser J, Polu KR, Moller CC et al (2005) TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet 37:739–744PubMedCentralPubMedCrossRef
9.
Lowik MM, Groenen PJ, Pronk I et al (2007) Focal segmental glomerulosclerosis in a patient homozygous for a CD2AP mutation. Kidney Int 72:1198–1203PubMedCrossRef
10.
11.
12.
Guigonis V, Dallocchio A, Baudouin V et al (2008) Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 23:1269–1279PubMedCrossRef
13.
Munyentwali H, Bouachi K, Audard V et al (2013) Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int 83:511–516PubMedCrossRef
14.
Ravani P, Ponticelli A, Siciliano C et al (2013) Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int 84:1025–1033PubMedCrossRef
15.
Zhang S, Audard V, Fan Q et al (2011) Immunopathogenesis of idiopathic nephrotic syndrome. Contrib Nephrol 169:94–106PubMedCrossRef
16.
Yap HK, Cheung W, Murugasu B et al (1999) Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse. J Am Soc Nephrol 10:529–537PubMed
17.
Lai KW, Wei CL, Tan LK et al (2007) Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats. J Am Soc Nephrol 18:1476–1485PubMedCrossRef
18.
Van Den Berg JG, Aten J, Chand MA et al (2000) Interleukin-4 and interleukin-13 act on glomerular visceral epithelial cells. J Am Soc Nephrol 11:413–422
19.
Zhu P, Goh YY, Chin HF et al (2012) Angiopoietin-like 4: a decade of research. Bioscience reports 32:211–219PubMedCrossRef
20.
Koliwad SK, Gray NE, Wang JC. Angiopoietin-like 4 (Angptl4) (2012): A glucocorticoid-dependent gatekeeper of fatty acid flux during fasting. Adipocyte.1:182–187.
21.
Koliwad SK, Kuo T, Shipp LE et al (2009) Angiopoietin-like 4 (ANGPTL4, fasting-induced adipose factor) is a direct glucocorticoid receptor target and participates in glucocorticoid-regulated triglyceride metabolism. J Biol Chem 284:25593–25601PubMedCentralPubMedCrossRef
22.
Koster A, Chao YB, Mosior M et al (2005) Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. Endocrinology 146:4943–4950PubMedCrossRef
23.
Clement LC, Avila-Casado C, Mace C et al (2011) Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat Med 17:117–122PubMedCentralPubMedCrossRef
24.
25.
Garin EH, Diaz LN, Mu W, Wasserfall C et al (2009) Urinary CD80 excretion increases in idiopathic minimal-change disease. J Am Soc Nephrol 20: 260–266.
26.
Garin EH, MuW, Arthur JMet al (2010) Urinary CD80 is elevated in minimal change di sease but not in focal s egmental glomerulosclerosis. Kidney Int 78:296–302
27.
Navarro-Munoz M, Ibernon M, Perez V et al (2011) Messenger RNA expression of B7-1 and NPHS1 in urinary sediment could be useful to differentiate between minimal-change disease and focal segmental glomerulosclerosis in adult patients. Nephrol Dial Transplant 26:3914–3923PubMedCrossRef
28.
Yu CC, Fornoni A, Weins A et al (2013) Abatacept in B7-1-Positive Proteinuric Kidney Disease. N Engl J Med 2013
29.
Sahali D, Pawlak A, Valanciute A et al (2002) A novel approach to investigation of the pathogenesis of active minimal-change nephrotic syndrome using subtracted cDNA library screening. J Am Soc Nephrol 13:1238–1247PubMed
30.
Grimbert P, Valanciute A, Audard V et al (2003) Truncation of C-mip (Tc-mip), a new proximal signaling protein, induces c-maf Th2 transcription factor and cytoskeleton reorganization. J Exp Med 198:797–807PubMedCentralPubMedCrossRef
31.
Kamal M, Valanciute A, Dahan K et al (2009) C-mip interacts physically with RelA and inhibits nuclear factor kappa B activity. Mol Immunol 46:991–998PubMedCrossRef
32.
Zhang SY, Kamal M, Dahan K et al. (2010) c-mip impairs podocyte proximal signaling and induces heavy proteinuria. Sci Signal 3:ra39.
33.
Audard V, Zhang SY, Copie-Bergman C et al (2010) Occurrence of minimal change nephrotic syndrome in classical Hodgkin lymphoma is closely related to the induction of c-mip in Hodgkin-Reed Sternberg cells and podocytes. Blood 115:3756–3762PubMedCentralPubMedCrossRef
34.
Cambier JF, Ronco P (2012) Onco-nephrology: glomerular diseases with cancer. Clin J Am Soc Nephrol 7:1701–1712PubMedCrossRef
35.
Sendeyo K, Audard V, Zhang SY et al (2013) Upregulation of c-mip is closely related to podocyte dysfunction in membranous nephropathy. Kidney Int 83:414–425PubMedCentralPubMedCrossRef
36.
Ory V, Fan Q, Hamdaoui N et al (2012) c-mip down-regulates NF-kappaB activity and promotes apoptosis in podocytes. Am J Pathol 180:2284–2292PubMedCrossRef
37.
Patrakka J, Tryggvason K (2007) Nephrin—a unique structural and signaling protein of the kidney filter. Trends Mol Med 13:396–403PubMedCrossRef
38.
39.
Huber TB, Hartleben B, Kim J et al (2003) Nephrin and CD2AP associate with phosphoinositide 3-OH kinase and stimulate AKT-dependent signaling. Mol Cell Biol 23:4917–4928PubMedCentralPubMedCrossRef
40.
Quack I, Rump LC, Gerke P et al (2006) beta-Arrestin2 mediates nephrin endocytosis and impairs slit diaphragm integrity. Proc Natl Acad Sci U S A 103:14110–14115PubMedCentralPubMedCrossRef
41.
Uchida K, Suzuki K, Iwamoto M et al (2008) Decreased tyrosine phosphorylation of nephrin in rat and human nephrosis. Kidney Int 73:926–932PubMedCrossRef
42.
Foster RR, Saleem MA, Mathieson PW et al (2005) Vascular endothelial growth factor and nephrin interact and reduce apoptosis in human podocytes. Am J Physiol Renal Physiol 288:F48–F57PubMedCrossRef
43.
44.
Schiffer M, Mundel P, Shaw AS et al (2004) A novel role for the adaptor molecule CD2-associated protein in transforming growth factor-beta-induced apoptosis. J Biol Chem 279:37004–37012PubMedCrossRef
45.
Shih NYLJ, Karpitskii V, Nguyen A et al (1999) Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science 286:312–315PubMedCrossRef
46.
Sakai N, Wada T, Furuichi K et al (2002) p38 MAPK phosphorylation and NF-kappa B activation in human crescentic glomerulonephritis. Nephrol Dial Transplant 17:998–1004PubMedCrossRef
47.
Stambe C, Nikolic-Paterson DJ, Hill PA et al (2004) p38 Mitogen-activated protein kinase activation and cell localization in human glomerulonephritis: correlation with renal injury. J Am Soc Nephrol 15:326–336PubMedCrossRef
48.
Koshikawa M, Mukoyama M, Mori K et al (2005) Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome. J Am Soc Nephrol 16:2690–2701PubMedCrossRef
49.
Mima A, Kitada M, Geraldes P et al (2012) Glomerular VEGF resistance induced by PKCdelta/SHP-1 activation and contribution to diabetic nephropathy. FASEB J 26:2963–2974PubMedCentralPubMedCrossRef
50.
Emoto Y, Manome Y, Meinhardt G et al (1995) Proteolytic activation of protein kinase C delta by an ICE-like protease in apoptotic cells. EMBO J 14:6148–6156PubMedCentralPubMed
51.
Kamal M, Pawlak BMAF et al (2010) C-mip interacts with the p85 subunit of PI3 kinase and exerts a dual effect on ERK signaling via the recruitment of Dip1 and DAP kinase. FEBS Lett 584:500–506PubMedCrossRef
52.
Wang WJ, Kuo JC, Yao CC et al (2002) DAP-kinase induces apoptosis by suppressing integrin activity and disrupting matrix survival signals. J Cell Biol 159:169–179PubMedCentralPubMedCrossRef
53.
54.
55.
Sison K, Eremina V, Baelde H et al (2010) Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol 21:1691–1701PubMedCentralPubMedCrossRef
56.
Veron D, Reidy KJ, Bertuccio C et al (2010) Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease. Kidney Int 77:989–999PubMedCrossRef
57.
Ivy SP, Wick JY, Kaufman BM (2009) An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 6:569–579PubMedCrossRef
58.
Izzedine H, Massard C, Spano JP et al (2010) VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 46:439–448PubMedCrossRef
59.
Echeverria V, Burgess S, Gamble-George J et al (2009) Sorafenib inhibits nuclear factor kappa B, decreases inducible nitric oxide synthase and cyclooxygenase-2 expression, and restores working memory in APPswe mice. Neuroscience 162:1220–1231PubMedCrossRef
60.
Niaudet P, Gagnadoux MF, Broyer M (1998) Treatment of childhood steroid-resistant idiopathic nephrotic syndrome. Adv Nephrol Necker Hosp 28:43–61PubMed
61.
62.
Ramos EL (1991) Recurrent diseases in the renal allograft. J Am Soc Nephrol 2:109–121PubMed
63.
Fairhead T, Knoll G (2010) Recurrent glomerular disease after kidney transplantation. Curr Opin Nephrol Hypertens 19:578–585PubMedCrossRef
64.
Canaud G, Martinez F, Noel LH et al (2010) Therapeutic approach to focal and segmental glomerulosclerosis recurrence in kidney transplant recipients. Transplant Rev (Orlando) 24:121–128CrossRef
65.
66.
Hoyer JR, Vernier RL, Najarian JS et al (1972) Recurrence of idiopathic nephrotic syndrome after renal transplantation. Lancet 2:343–348PubMedCrossRef
67.
Kemper MJ, Wolf G, Muller-Wiefel DE (2001) Transmission of glomerular permeability factor from a mother to her child. N Engl J Med 344:386–387PubMedCrossRef
68.
Ali AA, Wilson E, Moorhead JF et al (1994) Minimal-change glomerular nephritis. Normal kidneys in an abnormal environment? Transplantation 58:849–852PubMedCrossRef
69.
Rea R, Smith C, Sandhu K et al (2001) Successful transplant of a kidney with focal segmental glomerulosclerosis. Nephrol Dial Transplant 16:416–417PubMedCrossRef
70.
Feld SMFP, Savin V, Nast CC (1998) Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis in native kidneys. Am J Kidney Dis 32:230–237PubMedCrossRef
71.
Ginsburg DSDP (1997) Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis. Clin Nephrol 48:282–287PubMed
72.
Dantal J, Bigot E, Bogers W et al (1994) Effect of plasma protein adsorption on protein excretion in kidney- transplant recipients with recurrent nephrotic syndrome [see comments]. N Engl J Med 330:7–14PubMedCrossRef
73.
Dantal J, Godfrin Y, Koll R et al (1998) Antihuman immunoglobulin affinity immunoadsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome. J Am Soc Nephrol 9:1709–1715PubMed
74.
Savin VJ, Sharma R, Sharma M et al (1996) Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 334:878–883PubMedCrossRef
75.
Boulton Jones JM, Tulloch I, Dore B et al (1983) Changes in the glomerular capillary wall induced by lymphocyte products and serum of nephrotic patients. Clin Nephrol 20:72–77PubMed
76.
Yoshizawa N, Kusumi Y, Matsumoto K et al (1989) Studies of a glomerular permeability factor in patients with minimal-change nephrotic syndrome. Nephron 51:370–376PubMedCrossRef
77.
Koyama A, Fujisaki M, Kobayashi M et al (1991) A glomerular permeability factor produced by human T cell hybridomas. Kidney Int 40:453–460PubMedCrossRef
78.
McCarthy ET, Sharma M, Savin VJ (2010) Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 5:2115–2121PubMedCrossRef
79.
80.
Eugen-Olsen J, Andersen O, Linneberg A et al (2010) Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 268:296–308PubMedCrossRef
81.
Bock ME, Price HE, Gallon L, Langman CB (2013) Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report. Clin J Am Soc Nephrol 8:1304–1311PubMedCentralPubMedCrossRef
82.
Maas RJ, Wetzels JF, Deegens JK (2012) Serum-soluble urokinase receptor concentration in primary FSGS. Kidney Int 81:1043–1044PubMedCrossRef
83.
84.
Franco Palacios CR, Lieske JC, Wadei HM et al (2013) Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation 96:394–399PubMedCrossRef
85.
Beaudreuil S, Zhang X, Kriaa F et al. (2013) Protein A immunoadsorption cannot significantly remove the soluble receptor of urokinase from sera of patients with recurrent focal segmental glomerulosclerosis. Nephrol Dial Transplant. Nov 13 [Epub ahead of print].
86.
Metadata
Title
Immunopathogenesis of idiopathic nephrotic syndrome with relapse
Authors
Djillali Sahali
Kelhia Sendeyo
Melanie Mangier
Vincent Audard
Shao Yu Zhang
Philippe Lang
Mario Ollero
Andre Pawlak
Publication date
01-07-2014
Publisher
Springer Berlin Heidelberg
Published in
Seminars in Immunopathology / Issue 4/2014
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-013-0415-3

Other articles of this Issue 4/2014

Seminars in Immunopathology 4/2014 Go to the issue

Editorial

Ten-year advances in immunopathology of glomerulonephritis: translated into patients’ care or lost in translation?

Review

Immunopathology of lupus nephritis

Review

Update on crescentic glomerulonephritis

Review

New insights into the pathogenesis of IgA nephropathy

Review

The immunopathology of ANCA-associated vasculitis

Review

Immunopathogenesis of membranous nephropathy: an update
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits